A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms.
Functional connectivity
Ketamine
Psychosis
Resting state
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
09
2018
revised:
24
02
2019
accepted:
27
02
2019
pubmed:
11
3
2019
medline:
27
12
2019
entrez:
11
3
2019
Statut:
ppublish
Résumé
Ketamine is an uncompetitive N-methyl-d-aspartate (NMDA) glutamate receptor antagonist. It induces effects in healthy individuals that mimic symptoms associated with schizophrenia. We sought to root these experiences in altered brain function, specifically aberrant resting state functional connectivity (rsfMRI). In the present study, we acquired rsfMRI data under ketamine and placebo in a between-subjects design and analyzed seed-based measures of rsfMRI using large-scale networks, dorsolateral prefrontal cortex (DLPFC) and sub-nuclei of the thalamus. We found ketamine-induced alterations in rsfMRI connectivity similar to those seen in patients with schizophrenia, some changes that may be more comparable to early stages of schizophrenia, and other connectivity signatures seen in patients that ketamine did not recreate. We do not find any circuits from our regions of interest that correlates with positive symptoms of schizophrenia in our sample, although we find that DLPFC connectivity with ACC does correlate with a mood measure. These results provide support for ketamine's use as a model of certain biomarkers of schizophrenia, particularly for early or at-risk patients.
Identifiants
pubmed: 30852397
pii: S2213-1582(19)30089-0
doi: 10.1016/j.nicl.2019.101739
pmc: PMC6411494
pii:
doi:
Substances chimiques
Excitatory Amino Acid Antagonists
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101739Subventions
Organisme : NIDA NIH HHS
ID : HHSN271201200007C
Pays : United States
Organisme : NINDS NIH HHS
ID : T32 NS041228
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Inc.
Références
Neuroimage. 2007 Aug 1;37(1):90-101
pubmed: 17560126
Acta Neuropathol. 2009 Apr;117(4):369-84
pubmed: 18642008
Cereb Cortex. 2014 Dec;24(12):3116-30
pubmed: 23825317
Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Sep;1(5):393-400
pubmed: 28626813
Brain Connect. 2012;2(3):125-41
pubmed: 22642651
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1279-84
pubmed: 19164577
Neuron. 2011 Nov 17;72(4):665-78
pubmed: 22099467
Anesthesiology. 2016 Nov;125(5):873-888
pubmed: 27496657
Neuroimage. 2005 May 1;25(4):1325-35
pubmed: 15850749
Trends Cogn Sci. 2016 Feb;20(2):96-106
pubmed: 26704857
Curr Pharm Biotechnol. 2018;19(4):293-307
pubmed: 29929462
Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33
pubmed: 12955285
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11073-8
pubmed: 17576922
Annu Rev Med. 2015;66:509-23
pubmed: 25341010
Schizophr Bull. 2014 Mar;40(2):428-37
pubmed: 23519021
Schizophr Bull. 2017 Mar 1;43(2):436-448
pubmed: 27445261
Mol Psychiatry. 2013 Nov;18(11):1199-204
pubmed: 23337947
Nat Neurosci. 2003 Jul;6(7):750-7
pubmed: 12808459
Front Psychol. 2012 Oct 12;3:392
pubmed: 23091464
Schizophr Bull. 2014 Nov;40(6):1227-43
pubmed: 25031221
Psychol Med. 2018 Nov;48(15):2492-2499
pubmed: 29444726
Neuroimage Clin. 2017 Oct 19;17:335-346
pubmed: 29159045
JAMA Psychiatry. 2018 Jan 1;75(1):11-19
pubmed: 29167877
Schizophr Res. 2014 Dec;160(1-3):43-50
pubmed: 25458571
Adv Pharmacol. 2016;76:351-82
pubmed: 27288082
Neuroimage Clin. 2018 Jun 01;19:745-757
pubmed: 30003027
CNS Spectr. 2008 Aug;13(8):663-81
pubmed: 18704022
Psychopharmacology (Berl). 2015 Dec;232(24):4515-24
pubmed: 26438425
Cereb Cortex. 2018 Feb 1;28(2):726-737
pubmed: 29161362
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19944-9
pubmed: 24248372
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82
pubmed: 11209064
Annu Rev Neurosci. 2015 Jul 8;38:433-47
pubmed: 25938726
Neuroimage Clin. 2017 Dec 05;17:704-716
pubmed: 29264112
PeerJ. 2014 May 01;2:e367
pubmed: 24860698
Eur Neuropsychopharmacol. 2016 Jun;26(6):994-1003
pubmed: 27133029
Biol Psychiatry. 2012 Nov 1;72(9):785-94
pubmed: 22717030
Neuropsychopharmacology. 2013 Dec;38(13):2613-22
pubmed: 23856634
J Psychopharmacol. 2007 May;21(3):238-52
pubmed: 17591652
Neuroimage. 2012 Jan 16;59(2):1420-8
pubmed: 21889994
Neurosci Biobehav Rev. 2016 Feb;61:108-20
pubmed: 26698018
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16720-5
pubmed: 23012427
Schizophr Bull. 2014 Sep;40(5):1095-104
pubmed: 24243441
J Psychopharmacol. 2014 Apr;28(4):287-302
pubmed: 24257811
Neuroimage. 2013 Jan 1;64:75-90
pubmed: 23009959
Arch Gen Psychiatry. 2006 Jun;63(6):611-21
pubmed: 16754834
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
pubmed: 8122957
Hum Brain Mapp. 2018 Feb;39(2):644-661
pubmed: 29105239
Biol Psychiatry. 2015 Mar 15;77(6):569-80
pubmed: 25281999
Front Hum Neurosci. 2014 Nov 28;8:940
pubmed: 25506321
Brain. 2007 Sep;130(Pt 9):2387-400
pubmed: 17690132
Neuropharmacology. 2014 Nov;86:174-80
pubmed: 25063581
Schizophr Res. 2010 Nov;123(2-3):105-15
pubmed: 20724114
Neurosci Biobehav Rev. 2015 Jul;54:57-75
pubmed: 25616183
Biol Psychiatry. 2017 May 15;81(10):874-885
pubmed: 28434616
Front Behav Neurosci. 2014 May 30;8:171
pubmed: 24910597
JAMA Psychiatry. 2015 Sep;72(9):882-91
pubmed: 26267151